

UNIVERSITÀ DEGLI STUDI DI PERUGIA

*Dipartimento di Medicina Clinica e Sperimentale*

**Sezione di Medicina del Lavoro, Malattie Respiratorie e  
Tossicologia Professionali e Ambientali**

*Direttore Prof. Giacomo Muzi*

# **Effetti biologici precoci delle esposizione ambientali sull'apparato respiratorio**

*Terni 14 Settembre 2018*

SENTIERI DA PERCORRERE


SALUTE E AMBIENTE A TERNI: CONOSCENZE ATTUALI E PROSPETTIVE  
DI STUDIO E INTERVENTO

## **Nicola Murgia**



---

Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia  
Professionali e Ambientali - Università degli Studi di Perugia




**Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia  
Professionali e Ambientali - Università degli Studi di Perugia**



**Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia  
Professionali e Ambientali - Università degli Studi di Perugia**

# Broncopneumopatie professionali e ambientali



II secolo



XXI secolo



# Spirometria

XVII secolo








XX secolo



XIX secolo





UNIVERSITA' DEGLI STUDI DI PERUGIA - AZIENDA OSPEDALIERA DI PERUGIA  
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE  
MEDICINA DEL LAVORO, MALATTIE RESPIRATORIE E TOSSICOLOGIA  
PROFESSIONALI ED AMBIENTALI

Ospedale S. Maria della Misericordia - Perugia - Loc. S. Andrea delle Fratte  
Lab. Fisiopatologia Respiratoria - Tel. 075/5784444 - 5784466

-----  
paz.: PAOLO sesso: M d.n.:  
c.f.: g.e.: alt.: 165 eta':  
cod.: peso: 85.0 c.r.:  
ind.: amb.

-----  
data: 25/10/2012

cartella n: 34025

VALORI SPIROMETRICI BASALI

		oss.	teorici	%	lim.
VC	l	4.08	3.06	133	2.14-3.98
FVC	l	4.08	2.97	137	1.97-3.97
<u>FEV1</u>	l	<u>2.51</u>	2.17	<u>116</u>	1.33-3.01
FEV1/VC	%	<u>61.45</u>	72.17	85	60.4-84.0
FEF25-75	l/s	1.06	2.29	46	0.58-4.00
FEF25-75/VC	l/s	0.26			
PEF	l/s	5.97	6.68	89	4.69-8.67
MEF75	l/s	4.74	6.10	78	3.29-8.91
MEF50	l/s	1.50	3.30	46	1.13-5.47
MEF25	l/s	0.33	0.78	42	-0.50-2.06

Teorici di Riferimento: Polgar 71 (6<eta'<18) ERS93 (18<=eta')



# Valutazione degli effetti precoci e reversibili sull'apparato respiratorio



- Espettorato indotto
- Ossido nitrico esalato
- Condensato dell'aria espirata
- Ricerca mutazioni in sangue e urine
- Citologia nasale e e buccale



# Valutazione degli effetti precoci e reversibili sull'apparato respiratorio

- **Espettorato indotto**
- **Ossido nitrico esalato**
- **Condensato dell'aria espirata**
- **Ricerca mutazioni in sangue e urine**
- **Citologia nasale e buccale**





<A7>

Parma 11-14 September 2011

*Breath Analysis Summit 2011 - International Conference on Breath Research*

## **Oxidative stress and airway inflammation in workers exposed to crystalline silica and in patient with silicosis assessed by lung function tests and exhaled breath condensate**

Murgia N.<sup>1</sup>, Montuschi P.<sup>2</sup>, Gambelunghe A.<sup>1</sup>, Dell'Omo M.<sup>1</sup>, Ciabattoni G.<sup>3</sup>, Abbritti G.<sup>1</sup>, Muzi G.<sup>1</sup>

<sup>1</sup>Section of Occupational Medicine, Respiratory Diseases and Occupational and Environmental Toxicology, University of Perugia, Italy. <sup>2</sup>Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy. <sup>3</sup>Department of Drug Sciences, School of Pharmacy, University of Chieti "G. d'Annunzio", Chieti, Italy




Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia  
Professionali e Ambientali - Università degli Studi di Perugia

## Characteristics of subjects – no smokers

	Non smokers (n=37)						p
	Non exposed n=8		Healthy exposed n=21		Silicosis n=8		
	median	min-max	median	min-max	median	min-max	
Age (yrs)	31	26-42	34	23-52	36.5	30-53	NS
Silica exposure (yrs)	/	/	12	1-22	15	6-37	NS
<i>Pulmonary function</i>							
FVC (% p.v. )	103	96-122	103	75-123	101	82-114	NS
FEV1 (% p.v. )	103	97-135	103	78-121	98	83-120	NS
TLC (% p.v. )	99	93-118	100.5	78-116	98.5	79-110	NS
RV (% p.v. )	86	78-106	82.5	66-134	87	74-140	NS
DLCO (% p.v. )	92	77-111	100	60-130	96	67-113	NS




# 8-isoprostane in exhaled breath condensate



*Murgia et BAS 2011*




# Induced sputum, exhaled breath condensate and nasal lavage fluid in electroplating workers exposed to chromium.



Murgia et al Int J Immunophatol Pharmacol 200



# Nitrite and oral hygiene



Zetterquist W et al Res Med 2009





**REVIEW**

## The role of non-invasive biomarkers in detecting acute respiratory effects of traffic-related air pollution

M. C. Scarpa<sup>1</sup>, N. Kulkarni<sup>2</sup> and P. Maestrelli<sup>1</sup>

<sup>1</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy and <sup>2</sup>Institute for Lung Health, Glenfield Hospital, Leicester, UK

---

This survey of the current literature displays the complexity of this research field, highlights the significance of short-term studies on traffic-related air pollution and gives important tips when planning studies to detect acute respiratory effects of pollution in a non-invasive way.



# Nuovi metodi di valutazione degli effetti precoci e reversibili sull'apparato respiratorio

- **Naso elettronico (eNose)**
- **Particelle esalate (PexA)**






Clean  
air




A




B




C



D



E




F

Pattern  
0


Patient  
1




A




B




C



D



E




F

Pattern  
1

Patient  
2



A



B




C



D



E



F


Pattern  
2



Sensors



# Airway disease and breathprints




Montuschi P et al Chest

2010



# Airway disease and breathprints

Asthma : red  
COPD : blue



*Fens N et al AJRCCM 2009*




# Nuovi metodi di valutazione degli effetti precoci e reversibili sull'apparato respiratorio


- **Naso elettronico (eNose)**
- **Particelle esalate (PexA)**



# Cytokines and Chemokines.



# Exhaled particle collection



*Almstrand AC et al. Anal  
Chem 2009*



Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia  
Professionali e Ambientali - Università degli Studi di Perugia

# Exhaled particle analysis

Subject	PEX-SP-A (au)		EBC-SP-A (au)	
	Session 1	Session 2	Session 1	Session 2
1	1.4	1.5	<LoD	<LoD
2	4.0	3.3	<LoD	0.76
3	3.5	2.7	<LoD	<LoD
4	3.4	2.8	<LoD	<LoD
5	2.2	1.9	1.65	<LoD
6	2.5	3.0	0.57	<LoD
7	2.1	2.8	<LoD	0.48
8	2.2	3.0	<LoD	<LoD
9	2.4	2.2	<LoD	<LoD
Median (Q1–Q3)	2.6 (2.2–3.0)		—	


*Larsson P et al Res Med 2012*



# Valutazione degli effetti precoci e reversibili sull'apparato respiratorio

- Espettorato indotto
- Ossido nitrico esalato
- Condensato dell'aria espirata
- **Ricerca mutazioni in sangue e urine**
- **Citologia nasale e buccale**







# Nuovi metodi di valutazione degli effetti precoci e reversibili sull'apparato respiratorio

- **Modificazioni epigenetiche**
  - miRNA
  - Metilazione del DNA
  - Modificazione degli istoni







## MicroRNAs as Potential Signatures of Environmental Exposure or Effect: A Systematic Review

Karen Vrijens,<sup>1</sup> Valentina Bollati,<sup>2</sup> and Tim S. Nawrot<sup>1,3</sup>

<sup>1</sup>Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium; <sup>2</sup>Center of Molecular and Genetic Epidemiology, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; <sup>3</sup>Department of Public Health and Primary Care, Environment and Health Unit, Leuven University, Leuven, Belgium

**Table 1.** miRNAs that are responsive to personal or environmental exposure and their roles in human disease.

miRNA	Regulated	Exposure	Diseases	Sources
Let-7e	Down	TCDD	HCC, lung, pituitary, and breast cancer, GEP tumors	Feitelson and Lee 2007; Qian et al. 2009; Rahman et al. 2009; Sakurai et al. 2012; Takamizawa et al. 2004
	Up	RDX	Heart failure, asthma	
Let-7g	Down	BPA, PM	Lung carcinoma, GEP tumors, breast cancer	Rahman et al. 2009; Sakurai et al. 2012
miR-9	Down	PM	Brain cancer, Huntington's disease	Ferretti et al. 2009; Lau and de Strooper 2010
	Up	Aluminum	Hodgkin lymphoma, breast cancer	
miR-10b	Down	Formaldehyde, PM	Gastric cancer	Kim K et al. 2011
miR-21	Down	Smoking	Diabetes type 2	Zampetaki et al. 2010
	Up	DEP, metal-rich PM	Breast cancer, glioblastoma, neo-intimal lesions, cardiac hypertrophy, atherosclerosis	
miR-26b	Down	DEP, BPA, PFOA	Schizophrenia, CRC, breast cancer	Earle et al. 2010; Liu et al. 2011; Perkins et al. 2007
miR-31	Down	DEP, TCDD	Medulloblastoma, T-cell leukemia	Ferretti et al. 2009; Yamagishi et al. 2012
miR-34b	Down	Smoking (2x)	CRC, pancreatic, mammary, ovarian, and renal cell carcinoma	Vogt et al. 2011
miR-92b	Down	Smoking, DDT	Medulloblastoma	Genovesi et al. 2011
miR-122	Down	Smoking	HCC	Bai et al. 2009
	Up	TCDD	Hepatitis C, renal cell carcinoma, male infertility, sepsis, hyperlipidemia	
miR-125b	Down	Smoking (2x)	Breast cancer, head and neck cancer	Nakanishi et al. 2014; Zhang et al. 2011
	Up	Aluminum sulfate (2x)	Endometriosis, cardiac hypertrophy, Alzheimer's disease	

..continua



# Conclusioni

- **Metodi validati ancora attuali ma non sufficienti a valutare i danni precoci**
- **Vecchi metodi non invasivi per studiare l'infiammazione possono essere utili (FeNO)**
- **Nuovi metodi per studiare l'infiammazione ancora da validare**
- **Valutazione dei danni genetici (.....)**
- **Epigenetica promettente ma ancora costosa e in espansione**

